Alternate Formula Feedings in Formula Intolerant Infants
NCT ID: NCT02456805
Last Updated: 2015-05-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
113 participants
INTERVENTIONAL
1996-08-31
1997-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Infant Formula 1
A standard commercial milk-based infant formula
Infant Formula 1
Feed ab libitum
Infant Formula 2
A standard commercial soy-based infant formula.
Infant Formula 2
Feed ab libitum
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Infant Formula 1
Feed ab libitum
Infant Formula 2
Feed ab libitum
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Infants whose physicians had made a recommendation that the parents change the infant's feeding.
* Full term infants at birth with a gestational age of 37 to 42 weeks.
* Infants 2- 9 weeks of age at study entry with birth weights greater than 2500 grams.
Exclusion Criteria
* Infants with evidence of cardiac, respiratory, gastrointestinal, hematological, or metabolic disease.
2 Weeks
9 Weeks
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott Nutrition
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Lasekan, MBA, Ph.D, CCRP
Role: STUDY_CHAIR
Abbott Nutrition
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arkansas Children's Hospital
Little Rock, Alaska, United States
Aurora Pediatric Associates
Aurora, Colorado, United States
Northlake Pediatric, Associates
Stone Mountain, Georgia, United States
The Medical Associates Clinic
Dubuque, Iowa, United States
Baystate Medical Center, Children's Hospital
Springfield, Massachusetts, United States
Clinical Studies, Inc
Canton, Ohio, United States
Richmond Pediatrics
Richmond, Virginia, United States
Optimum Clinical Research
Oshawa, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AH23
Identifier Type: -
Identifier Source: org_study_id